Susquehanna International Group’s Xenetic Biosciences XBIO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-25,388
Closed -$66.3K 13842
2025
Q1
$66.3K Buy
25,388
+9,529
+60% +$37.3K ﹤0.01% 11762
2024
Q4
$63.9K Buy
+15,859
New +$64K ﹤0.01% 11578
2023
Q2
Sell
-7,782
Closed -$32.1K 13282
2023
Q1
$32.1K Buy
7,782
+5,278
+211% +$25.6K ﹤0.01% 11887
2022
Q4
$7.16K Buy
+2,504
New +$11K ﹤0.01% 11990
2022
Q3
Sell
-3,752
Closed -$30K 14241
2022
Q2
$30K Buy
+3,752
New +$30.3K ﹤0.01% 12226
2022
Q1
Sell
-12,711
Closed -$164K 14101
2021
Q4
$164K Buy
+12,711
New +$203K ﹤0.01% 11687
2019
Q4
Sell
-1,690
Closed -$20K 10782
2019
Q3
$20K Buy
+1,690
New +$60.4K ﹤0.01% 9951

Other funds holding XBIO

Susquehanna International Group's XBIO Position: Q2 2025 in Review

Susquehanna International Group sold out of Xenetic Biosciences (XBIO) in Q2 2025, closing a stake of 25,388 shares — an estimated $66.3K sold.

Susquehanna International Group first reported a position in XBIO in Q3 2019 and held it in 7 quarters. The position peaked at $164K in Q4 2021. 9 funds tracked by Wall St. Rank hold XBIO as of Q2 2025.

  • Susquehanna International Group reported no remaining Xenetic Biosciences position as of Q2 2025 after selling out during the quarter.
  • Susquehanna International Group sold 25,388 Xenetic Biosciences shares in Q2 2025, an estimated $66.3K.
  • Susquehanna International Group first reported a position in Xenetic Biosciences in Q3 2019 and held it in 7 quarters.
  • Susquehanna International Group's Xenetic Biosciences position peaked at $164K in Q4 2021.
  • 9 funds tracked by Wall St. Rank held Xenetic Biosciences as of Q2 2025.

Based on Susquehanna International Group's 13F filing for Q2 2025, filed 14 Aug 2025.